NCT03029052: CONCIVILLE

Medication Reconciliation at Discharge: Impact on Patient's Care

Completed NA Last updated 14 July 2020

What this trial tests

NA trial testing Reconciliation in Medication Reconciliation in 120 participants. Completed in 2 July 2019.

Timeline

8 February 2017

Primary endpoint
2 July 2019

2 July 2019

Quick facts

Lead sponsor	Centre d'Investigation Clinique et Technologique 805
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	8 February 2017
Primary completion	2 July 2019
Estimated completion	2 July 2019
Sites	1 location across France

Drugs / interventions tested

• Reconciliation

Conditions studied

• Medication Reconciliation — all drugs for Medication Reconciliation →

Sponsor

Centre d'Investigation Clinique et Technologique 805 — full company profile →

Who can join

Adults 18 to 100, any sex, with Medication Reconciliation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patient's discharge from hospital is associated with iatrogenic events for 12 to 17% of patients. This risk may be linked with discontinuity of care between hospital physicians and Primary Care Physician (PCP). The investigators aim to assess in this study the impact of medication reconciliation at discharge associated with a patient's counseling session, both provided by a pharmacist, on patient's care after discharge. To demonstrate the interest of medication reconciliation at discharge we expect a reduction by 15% of the number of prescription changes not maintained by the PCP after discharge.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Impact of medication reconciliation for improving transitions of care.
   Redmond P, Grimes TC, McDonnell R, Boland F, et al · · 2018 · cited 109× · PMID 30136718 · DOI 10.1002/14651858.cd010791.pub2